In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

In 2022, pharmaceutical giant Pfizer (NYSE: PFE) became the first healthcare company to generate $100 billion in annual sales ...

The pharma expects a modest financial headwind this year from changes to Medicare prescription drug benefits under the ...

President Trump has vowed to impose tariffs on China, Mexico, and Canada. They could make common medicines less affordable.

Maybe your mom reassured you when you were younger that the cough syrup would taste “just like candy” — usually cherry, but why cherry?

We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at ...

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report) and keeping the price target at $36.00.Stay ...

(Reuters) -A U.S. appeals court on Friday revived a lawsuit by a conservative group opposed to diversity initiatives in ...

A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s Arexvy and Pfizer’s Abrysvo, prompting the regulator to require adjustments ...